CTOs on the Move


 
At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer`s, so that patients can regain their memories, lives, and family relationships. We are a motivated, impassioned team committed to making a positive impact on human health.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.athira.com
  • 18706 North Creek Parkway Suite 104
    Bothell, WA USA 98011
  • Phone: 866.725.0930

Executives

Name Title Contact Details
Rachel Lenington
Chief Technology Officer and Head of Product Development Strategy Profile
Rachel Lenington
Chief Operating Officer Profile

Funding

Athira raised $85M on 06/04/2020
Athira raised $90M on 01/20/2021

Similar Companies

DestinationRX

DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theradex Oncology Experts

Theradex is an international contract research organization providing complete professional services for the clinical research and development of pharmaceutical compounds, medical devices and diagnostic tests in the areas of oncology and

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Sanofi Genzyme

Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

ADVANCED CELLULAR DYNAMICS

ADVANCED CELLULAR DYNAMICS is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.